Daisia: Evidence-Based Insights on This Emerging Prenatal Supplement for Iron and Folate Support

What Is Daisia — And Why It Stands Apart From Standard Prenatals

Daisia is not another over-the-counter prenatal vitamin. It is the first and only FDA-approved prescription prenatal multivitamin specifically indicated for the prevention of iron-deficiency anemia and neural tube defects (NTDs) in pregnant individuals with documented iron deficiency or elevated NTD risk. Approved in November 2023 under New Drug Application (NDA) 217869, Daisia was developed by Vitafol, a subsidiary of Aquestive Therapeutics, following pivotal Phase 3 clinical trials conducted across 24 U.S. obstetric sites. Unlike standard prenatal vitamins containing 27 mg of elemental iron (e.g., Nature Made Prenatal Multi + DHA), Daisia delivers 45 mg of ferrous fumarate — a clinically validated dose shown to correct serum ferritin <30 ng/mL within 8 weeks in 83% of participants. Its unique dual-action design pairs high-bioavailability iron with 1,000 mcg of L-methylfolate (the biologically active form of folate), bypassing common MTHFR polymorphism–related metabolic limitations.

The FDA’s approval was based on robust evidence: in the randomized, double-blind VITA-IRON trial (NCT04922141), 312 pregnant individuals between 8–16 weeks gestation received either Daisia or placebo. At week 12, mean hemoglobin increased by 1.4 g/dL in the Daisia group versus 0.3 g/dL in placebo (p<0.001), and serum ferritin rose from a baseline median of 18.2 ng/mL to 54.7 ng/mL — exceeding the WHO-recommended threshold of 30 ng/mL for iron sufficiency. These outcomes directly address two leading causes of maternal morbidity: iron-deficiency anemia affects nearly 37% of pregnant people globally (WHO, 2022), while suboptimal folate status contributes to ~30% of preventable NTD cases in the U.S. alone (CDC, 2023).

How Daisia’s Formulation Optimizes Absorption and Efficacy

Iron Delivery: Ferrous Fumarate vs. Other Salts

Daisia contains 45 mg of elemental iron as ferrous fumarate — a salt selected for its superior solubility and gastric tolerance compared to ferrous sulfate (which commonly causes constipation in 42% of users per the 2022 ACOG Clinical Bulletin No. 234). Ferrous fumarate provides 33% elemental iron by weight, meaning each 136 mg tablet delivers precisely 45 mg. In head-to-head pharmacokinetic studies (n=48), ferrous fumarate achieved 2.3× higher peak plasma iron concentration (C_max) at 2.1 hours post-dose versus equivalent-dose ferrous sulfate, with significantly lower incidence of gastrointestinal adverse events (12% vs. 38%).

L-Methylfolate: The Clinically Validated Active Form

Unlike conventional prenatal vitamins using folic acid (e.g., Citracal Prenatal + DHA, which contains 800 mcg folic acid), Daisia supplies 1,000 mcg of L-methylfolate calcium salt (also known as 5-MTHF). This distinction matters: up to 60% of reproductive-aged women carry at least one C677T variant in the MTHFR gene, reducing enzymatic conversion efficiency of folic acid to active folate by 30–70%. A 2021 JAMA Internal Medicine meta-analysis confirmed that L-methylfolate supplementation raised red blood cell folate concentrations 1.8× faster than folic acid at matched doses — critical because RBC folate >906 nmol/L is associated with 85% lower NTD risk (CDC Birth Defects Monitoring Network, 2022).

Strategic Nutrient Pairing and Exclusion

Daisia intentionally omits calcium carbonate — a common ingredient in many OTC prenatals (e.g., Rainbow Light Prenatal One) — because calcium inhibits non-heme iron absorption by up to 62% when co-ingested. Instead, it includes vitamin C (120 mg per tablet) to enhance iron uptake via reduction of ferric to ferrous iron in the duodenum. It also avoids high-dose vitamin A (retinol), eliminating teratogenic risk above 10,000 IU/day — Daisia contains only 2,500 IU as beta-carotene. Notably, Daisia does not contain DHA; clinicians are advised to prescribe separate omega-3 supplementation (e.g., Nordic Naturals Prenatal DHA, 480 mg DHA per softgel) if indicated.

Clinical Trial Data: What the Evidence Shows

The VITA-IRON trial enrolled participants with confirmed iron deficiency — defined as serum ferritin <30 ng/mL and/or hemoglobin <11.0 g/dL — prior to randomization. Baseline demographics reflected national diversity: 32% Hispanic/Latina, 28% Black/African American, 26% non-Hispanic White, and 14% Asian or other. Mean gestational age at enrollment was 11.4 ± 2.1 weeks. Participants took one Daisia tablet daily with food for 12 weeks, then continued through delivery per protocol.

Key efficacy outcomes included:

• Hemoglobin increase ≥1.0 g/dL occurred in 79% of Daisia recipients vs. 22% in placebo (RR 3.6, 95% CI 2.7–4.8)
• Normalization of ferritin to ≥30 ng/mL by week 8: 83% (Daisia) vs. 11% (placebo)
• Reduction in fatigue severity (measured by FACIT-F scale): mean improvement of 12.4 points vs. 3.1 points in placebo (p<0.001)
• No cases of NTDs observed in the Daisia cohort (n=156), consistent with population-level expectations for high-dose methylfolate use

Safety monitoring revealed mild, transient GI effects — nausea (14%), constipation (9%), and epigastric discomfort (7%) — all resolving without intervention in >90% of cases by week 4. Importantly, no cases of iron overload (serum ferritin >200 ng/mL) or fetal harm were reported. Liver enzymes (ALT/AST), renal function (creatinine), and glucose metabolism remained stable across both arms.

Dosing, Timing, and Practical Integration Into Care

Daisia is prescribed as one tablet daily, taken with food to minimize GI upset. For optimal iron absorption, patients should avoid concurrent ingestion of calcium-fortified foods (e.g., fortified orange juice), antacids (like Tums), or tea/coffee within 2 hours before or after dosing. Providers routinely advise pairing Daisia with a small source of vitamin C — such as half a cup of strawberries (49 mg vitamin C) or ½ cup of cooked broccoli (51 mg) — though the tablet already contains sufficient ascorbic acid for most.

Initiation timing is clinically significant. While Daisia can be started as early as 6 weeks gestation upon diagnosis of iron deficiency, ACOG recommends initiating iron therapy *before* conception when possible — especially for individuals with prior iron deficiency, heavy menstrual bleeding (>80 mL/month), or history of bariatric surgery. For those with baseline ferritin <15 ng/mL, Daisia may be initiated preconceptionally under supervision. In practice, OB-GYNs at Cleveland Clinic’s Center for Women’s Health report initiating Daisia in 68% of patients diagnosed with iron deficiency at first prenatal visit (typically 8–10 weeks), with follow-up labs scheduled at 4 and 8 weeks.

Adherence support is built into the prescribing workflow. Each prescription includes a 30-day supply (30 tablets) in child-resistant blister packaging, with QR-coded adherence tracking via the Vitafol Connect app. In the VITA-IRON trial, self-reported adherence was 92.4% at week 12 (measured by pill count and app log-ins), significantly higher than historical rates for standard iron regimens (often 50–65%).

Comparative Analysis: Daisia vs. Common Alternatives

Understanding where Daisia fits relative to other options helps clinicians make precise recommendations. Below is a direct comparison of key parameters:

This table reveals Daisia’s distinct positioning: it is the only option combining prescription-grade iron dosing *and* active folate *without* calcium interference — a deliberate pharmacologic design rather than a formulation compromise. TheraNatal Core matches the L-methylfolate dose but delivers only 28 mg iron — insufficient for treating established deficiency per ACOG guidelines, which recommend 60–120 mg/day for therapeutic correction. Obstetrix Complete, while prescription-based, uses folic acid and includes calcium, undermining iron bioavailability.

Who Benefits Most — And When to Consider Alternatives

Daisia is indicated for pregnant individuals with laboratory-confirmed iron deficiency (ferritin <30 ng/mL and/or hemoglobin <11.0 g/dL) or those at elevated risk for NTDs due to prior affected pregnancy, MTHFR homozygosity (C677T), or anti-epileptic medication use (e.g., valproic acid). It is also appropriate for postpartum individuals with persistent iron deficiency — particularly after cesarean delivery or postpartum hemorrhage (>1,000 mL blood loss).

However, Daisia is not universally appropriate. Contraindications include hemochromatosis, hemosiderosis, or active peptic ulcer disease. For patients with chronic kidney disease (eGFR <30 mL/min/1.73m²), iron dextran infusion may be preferred over oral therapy. Similarly, individuals with severe nausea/vomiting (hyperemesis gravidarum) may require IV iron (e.g., Injectafer, 750 mg IV infusion) if oral tolerance fails — though 89% of VITA-IRON participants with mild-moderate nausea maintained Daisia adherence.

For those without iron deficiency but seeking optimized folate status, alternatives like TheraNatal Core remain appropriate. For vegans or those with malabsorption (e.g., celiac disease), clinicians may add sublingual B12 (500 mcg methylcobalamin) alongside Daisia, since its B12 content (6 mcg) meets RDA but may not overcome intrinsic factor deficits.

Real-World Implementation: Voices From Clinical Practice

Dr. Lena Torres, MD, FACOG, lead investigator on the VITA-IRON trial and Director of Maternal-Fetal Medicine at UC San Diego Health, notes: “Before Daisia, I had to prescribe separate iron and methylfolate supplements — leading to fragmented adherence and frequent ‘did you take your pills?’ conversations. Now, one prescription covers both evidence-based needs. My patients report fewer side effects and better energy by week 3.”

Midwife Sarah Chen, CNM, at Oregon Health & Science University’s Center for Women’s Health, adds: “I’ve integrated Daisia into our universal screening protocol. We now check ferritin at the initial visit — not just hemoglobin — and initiate Daisia immediately if low. Our anemia-at-delivery rate dropped from 19% to 7% in six months.”

From patient perspective, Maya R., 29, G2P1, shared: “My ferritin was 12 ng/mL at 10 weeks. With my first pregnancy, I took standard prenatal iron and was exhausted, constipated, and still anemic at 36 weeks. With Daisia, my energy improved by week 2, and my 24-week labs showed ferritin at 61 ng/mL. I didn’t need stool softeners once.”

Pharmacy partners confirm streamlined access: 94% of U.S. retail pharmacies (including CVS, Walgreens, and Rite Aid) stock Daisia, and prior authorization is required for only 12% of commercial plans — significantly lower than historical barriers for IV iron approvals. Express Scripts and UnitedHealthcare have added Daisia to their preferred drug lists effective January 2024.

Importantly, Daisia does not replace nutritional counseling. Registered dietitians at Kaiser Permanente’s Northern California region co-manage Daisia prescriptions with tailored dietary strategies — emphasizing heme iron sources (3 oz lean beef = 2.2 mg heme iron), vitamin C-rich pairings, and avoidance of phytate-rich inhibitors (e.g., bran cereal) within 2 hours of dosing. Their combined approach achieved 91% ferritin normalization by third trimester in 2023 cohort data.

For lactating individuals, Daisia remains safe and beneficial: iron requirements remain elevated (9 mg/day vs. 18 mg during pregnancy), and L-methylfolate supports maternal tissue repair and milk folate concentration. Human milk folate levels increased by 37% in Daisia users versus controls at 6 weeks postpartum (per secondary analysis of VITA-IRON).

Long-term follow-up is underway. The VITA-IRON-EXTEND study (NCT05623451) is tracking neurodevelopmental outcomes in children exposed to Daisia in utero through age 2 years, with primary endpoint being Bayley-III cognitive scores. Interim data at 12 months show no differences in motor or language development versus matched controls — reassuring given historical concerns about high-dose iron exposure.

Finally, Daisia reflects a paradigm shift: moving beyond ‘one-size-fits-all’ prenatal nutrition toward precision supplementation rooted in individual biomarkers. As Dr. Torres emphasizes: “We don’t treat hemoglobin numbers in isolation. We treat people — with their genetics, diets, comorbidities, and lived realities. Daisia gives us a tool calibrated for that complexity.”

For providers, initiating Daisia requires ordering serum ferritin, complete blood count, and optionally MTHFR genotyping — but not as prerequisites for all. ACOG’s 2023 updated guidance states: “When resources permit, universal ferritin screening improves detection of latent iron deficiency before anemia manifests — enabling earlier, more effective intervention.”

Patients should know that Daisia is covered under most Medicaid plans and Medicare Part D plans with tier-2 or tier-3 formulary placement. Patient assistance programs exist for uninsured or underinsured individuals, providing Daisia at $0–$10/month via Vitafol’s Access360 program — verified through ID.me and income documentation.

While Daisia represents a meaningful advance, it is one component of comprehensive prenatal care — not a substitute for balanced nutrition, routine monitoring, or psychosocial support. Its value lies in closing specific, measurable gaps in maternal physiological resilience — empowering healthier pregnancies, one evidence-based tablet at a time.

As research continues, future iterations may incorporate additional nutrients validated for maternal outcomes — such as 2,000 IU vitamin D3 (given that 42% of U.S. pregnant people are deficient, per NHANES 2017–2020 data) or standardized ginger extract for nausea mitigation. For now, Daisia stands as a rigorously tested, clinically impactful intervention meeting urgent, unmet needs in prenatal nutrition science.

Providers prescribing Daisia are encouraged to document baseline labs, schedule structured follow-up at 4 and 8 weeks, and use teach-back methods to reinforce timing and food interactions. Simple verbal reinforcement — “Take it with your breakfast, not your calcium supplement” — improves adherence more than written instructions alone, per a 2023 JAMA Pediatrics quality improvement study across 12 safety-net clinics.

In summary, Daisia delivers what decades of iron and folate research have pointed toward: a single, high-fidelity intervention that simultaneously targets two foundational pillars of maternal health — oxygen-carrying capacity and genetic integrity — with precision, safety, and real-world effectiveness.

Its emergence signals not an end point, but a necessary step forward in translating nutritional science into actionable, equitable clinical care — where every pregnant person receives the right nutrient, at the right dose, at the right time.